U.S. GEN Release: 2017 Global Market Capitalization Top10 Pharmaceutical Company

founded in 1981 as the world's leading biotechnology media, GEN's website on November 27th published the 2017 Global TOP10 Pharmaceutical Company by Market Capitalization.
is this year's TOP10 Pharmaceuticals list, based on market capitalization as of November 9, 2017, from the company's website, stock trading sites and other public channels, and non-U.S. company data converted to U.S. dollars at the current exchange rate.
The world's top-value TOP10 pharmaceutical companies
pharmaceutical companies are relatively smoothoverall, traditional pharmaceutical companies have been more successful this year than biotech companies, and when biotech companies are caught up in the disappointments or failures of clinical trials in Q3, pharmaceutical companies have mostly looked smooth this year.
NYSE's ARCA Pharmaceuticals Index rose 7.8 percent to $536.86 as of November 9, 2017, while GEN's TOP10 pharmaceutical company has a market capitalization of 1.8 percent this year. $722 trillion, up 9.8 percent from $1.568 trillion last year and 5.9 percent from $1.626 trillion in TOP10 in 2015.GEN explains this with five factors: continued sales of heavy-bomb drugs that sold more than $1 billion in
;
's new FDA director, Scott Gottlieb, who simplified the process of listing new drugs and approved more new drugs;
the Trump administration's corporate tax cuts;
That Trump's policies to lower drug prices didn't materialise; and
pharmaceutical companies switched from big acquisitions to smaller, complementary acquisitions.GSK slipped out of the list, with The Year of Mercercompared with last year, with only one company, GlaxoSmithKline (6th in 2016), slipping out of the list, with a market capitalisation of 66.38 billion pounds ($87.29 billion), down 16 percent from $103.82 billion last year, and Lilly, which replaced GSK in top 10 with $86.63 billion last year.
More encouragingly, with the exception of Mercedon, the TOP10 pharmaceutical company's market capitalisation has increased this year compared with last year, with AbbVie and Bayer both up the rankings, while Mercedon slipped one place to sixth place from 2016, surpassing AbbVie, which was ranked 7th the year before.
October 27, 2017, Mercedon reported a 2% year-on-year decline in Q3 revenue, from $10,536 million in 2016 to $10,325 million. The drop in revenue provides several reasons, such as the $135 million loss of sales revenue due to a cyberattack on Mesa East this year, which actually came on the same day as a $240 million order for the U.S. CDC.
Other reasons are a 3% drop in drug sales to $9.2 billion, mainly due to the patent cliff faced by the downshift steroid drugs Zetia and Vytorin, Eytorin/Simvastatin, at the end of last year and in April of this year, respectively. In addition to losing market domination in the U.S., Cubest's antibiotic Cubicin, which was acquired at the end of 2014, faces competition from generics, as does Remicade, infringic, and biosimilars in Europe. (Medical representative)